GlassScriptPrepare for your visit
Khaled A Dajani
Cardiovascular Disease · Peoria, IL · NPI 1548294929
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$658.15
in general payments reported to CMS, 2019-2025 · $13.53 in 2025
Who reported paying
General payments only, top 6 by amount.
- Edwards Lifesciences Corporation $300.00
- Novartis Pharmaceuticals Corporation $221.41
- Amgen INC. $55.41
- Stryker Corporation $31.12
- Regeneron Pharmaceuticals, INC. $19.05
- United Therapeutics Corporation $17.63
Drugs and devices associated with these payments
Entresto Leqvio Repatha 1788 Tyvaso Eliquis
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Khaled Dajani listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/749096/khaled-a-dajani